Search research articles
Contact Us
Filters
Showing results (91-100 of 152) with videos related to
Page
of 16
Sort By:
Nuclear Medicine and Biology
|
May 22, 2017
Baseline and longitudinal variability of normal tissue uptake values of [<sup>18</sup>F]-fluorothymidine-PET images
Matthijs C F Cysouw, Gerbrand M Kramer, Virginie Frings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2012
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission
Sebastian Theurich, Joke Malcher, Kerstin Wennhold, et al.
European Journal of Haematology
|
August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial
Lutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
European Journal of Haematology
|
September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
February 13, 2021
Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach
Philipp Linde, Christian Baues, Simone Wegen, et al.
Molecular Imaging and Biology
|
June 30, 2022
Head-to-Head Comparison of [<sup>68</sup> Ga]Ga-FAPI-46-PET/CT and [<sup>18</sup>F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer
Simone Wegen, Lutz van Heek, Philipp Linde, et al.
Plos One
|
January 12, 2013
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib
Matthias Scheffler, Thomas Zander, Lucia Nogova, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma
Richard Riedel, Sebastian Michels, Carina Heydt, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 17, 2024
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
Johannes Rosenbrock, Helen Kaul, Michael Oertel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 4, 2024
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in <i>EGFR</i>-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance
Martin Schuler, Jörg Hense, Kaid Darwiche, et al.
Page
of 16
Search research articles
Search
Showing results (91-100 of 152) with videos related to
Sort By:
Page
of 16
Nuclear Medicine and Biology
|
May 22, 2017
Baseline and longitudinal variability of normal tissue uptake values of [<sup>18</sup>F]-fluorothymidine-PET images
Matthijs C F Cysouw, Gerbrand M Kramer, Virginie Frings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2012
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission
Sebastian Theurich, Joke Malcher, Kerstin Wennhold, et al.
European Journal of Haematology
|
August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial
Lutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
European Journal of Haematology
|
September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
February 13, 2021
Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach
Philipp Linde, Christian Baues, Simone Wegen, et al.
Molecular Imaging and Biology
|
June 30, 2022
Head-to-Head Comparison of [<sup>68</sup> Ga]Ga-FAPI-46-PET/CT and [<sup>18</sup>F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer
Simone Wegen, Lutz van Heek, Philipp Linde, et al.
Plos One
|
January 12, 2013
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib
Matthias Scheffler, Thomas Zander, Lucia Nogova, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma
Richard Riedel, Sebastian Michels, Carina Heydt, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 17, 2024
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
Johannes Rosenbrock, Helen Kaul, Michael Oertel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 4, 2024
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in <i>EGFR</i>-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance
Martin Schuler, Jörg Hense, Kaid Darwiche, et al.
Page
of 16